“If you look at the tubeless market, you know, we're seeing growth rates in excess of 25% annually,” Tandem Diabetes CEO John Sheridan explains to Bloomberg Intelligence about the growth opportunities in insulin pumps. In this episode of Vanguards of Health Care, Sheridan sits down with BI analyst Matt Henriksson for an in-depth interview about Tandem’s pending launch of Mobi Tubless, an insulin pump designed to wear on the body for discretion and the AI-powered Control-IQ Plus algorithm for simplicity. The conversation also touches on the company’s pay-as-you-go business model and future product development, including the next generation Mobi pumps utilizing Sigi technology from its AMF acquisition and a new closed loop algorithm.